New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 30, 2013
08:29 EDTALNYAlnylam completes ALN-TTR02 Phase II trial enrollment
Alnylam Pharmaceuticals announced that it has completed enrollment in its Phase II trial with ALN-TTR02. Recent interim results from this Phase II study showed that ALN-TTR02 achieved up to 93% knockdown of TTR, the disease-causing protein in ATTR. ALN-TTR02 activity was found to be rapid, dose dependent, and durable, with similar levels of TTR knockdown observed toward both wild-type and mutant protein. In addition, ALN-TTR02 was found to be generally safe and well tolerated in this study. Alnylam also announced today that its open-label extension study with ALN-TTR02 is open for enrollment. The OLE study will evaluate the long-term safety and tolerability of ALN-TTR02 and will also measure effects of treatment toward a number of clinical endpoints, including a Neuropathy Impairment Score, or “NIS.” The company intends to report clinical data from this study about once per year, with initial data in 2014.
News For ALNY From The Last 14 Days
Check below for free stories on ALNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:49 EDTALNYAlnylam resumed with an Outperform at Leerink
Subscribe for More Information
September 16, 2014
08:02 EDTALNYAlnylam presents ALN-CC5 pre-clinical data
Subscribe for More Information
September 15, 2014
08:01 EDTALNYAlnylam names Karen Anderson as SVP, Chief Human Resources Officer
Subscribe for More Information
07:21 EDTALNYHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 12, 2014
08:02 EDTALNYAlnylam broadens pipeline with ALN-AGT
Alnylam Pharmaceuticals announced that it is broadening its pipeline with ALN-AGT. In a poster presented at the American Heart Association’s High Blood Pressure Research 2014 Scientific Sessions, Alnylam and collaborators at the Charite Universitatsmedizin in Berlin presented results of an ALN-AGT lead molecule in an established preeclamptic rodent model. The study showed that administration of ALN-AGT resulted in knockdown of maternal AGT in the liver without detectable evidence of fetal drug exposure, significantly improved pregnancy-related hypertension, ameliorated preeclamptic sequelae in the mother such as proteinuria, and improved fetal outcomes.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use